[
    [
        {
            "time": "2021-12-03",
            "original_text": "贝达药业再度赴港IPO，去年营收18亿，超九成来自单一产品",
            "features": {
                "keywords": [
                    "贝达药业",
                    "IPO",
                    "营收",
                    "单一产品"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业再度赴港IPO，去年营收18亿，超九成来自单一产品",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "贝达药业重启赴港上市 寻求全球创新药物商业合作机遇",
            "features": {
                "keywords": [
                    "贝达药业",
                    "赴港上市",
                    "创新药物",
                    "商业合作"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业重启赴港上市 寻求全球创新药物商业合作机遇",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "益方生物IPO遭暂缓审议",
            "features": {
                "keywords": [
                    "益方生物",
                    "IPO",
                    "暂缓审议"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "益方生物IPO遭暂缓审议",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "明星创新药企IPO被终止：九年一事无成，在危险边缘疯狂试探？ IPO融资异常",
            "features": {
                "keywords": [
                    "创新药企",
                    "IPO",
                    "终止",
                    "融资异常"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "明星创新药企IPO被终止：九年一事无成，在危险边缘疯狂试探？ IPO融资异常",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "70万一针“天价药”纳入医保，多家上市公司公告来了",
            "features": {
                "keywords": [
                    "天价药",
                    "医保",
                    "上市公司"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "70万一针“天价药”纳入医保，多家上市公司公告来了",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "贝达药业再递表港交所，产品结构单一受质疑",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "产品结构单一",
                    "质疑"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业再递表港交所，产品结构单一受质疑",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "贝达药业递表港交所，今年前九月研发支出达3.62亿元",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "研发支出"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业递表港交所，今年前九月研发支出达3.62亿元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "贝达药业再递表港交所：收入高度依赖埃克替尼销售 涉与少数股东及独立第三方产品竞争诉讼 诉讼纠纷",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "埃克替尼",
                    "诉讼纠纷"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业再递表港交所：收入高度依赖埃克替尼销售 涉与少数股东及独立第三方产品竞争诉讼 诉讼纠纷",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "74种药品新增进入医保目录，这些公司产品榜上有名",
            "features": {
                "keywords": [
                    "药品",
                    "医保目录",
                    "公司产品"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "74种药品新增进入医保目录，这些公司产品榜上有名",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "贝达药业盐酸恩沙替尼（贝美纳）列入国家医保目录",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸恩沙替尼",
                    "医保目录"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业盐酸恩沙替尼（贝美纳）列入国家医保目录",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "贝达药业盐酸埃克替尼（凯美纳）术后辅助治疗适应症列入国家医保目录",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸埃克替尼",
                    "医保目录"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业盐酸埃克替尼（凯美纳）术后辅助治疗适应症列入国家医保目录",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]